Cite
HARVARD Citation
Alekseev, B. et al. (n.d.). 2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis. European journal of cancer. pp. S518-S519. [Online].